Skip to content
Peptigraph home

5-Amino-1MQ and SLU-PP-332 Together: What Is Known

5-Amino-1MQ and SLU-PP-332 taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
NNMT inhibitor (not a peptide)Not FDA approved · research chemical5-Amino-1MQNNMT inhibitor (not a peptide) with no human studies; in diet-induced obese mice, 5-amino-1MQ plus a low-fat diet promoted whole-body adiposity and weight loss.[2]GLP-1 & metabolicERR agonist (not a peptide)Not FDA approved · research chemicalSLU-PP-332Experimental ERR agonist (not a peptide) with no human studies; in mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, mimicking exercise.[6]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component

Side by side

Showing 5 of 11 fields where the two differ. Category, FDA status, PCAC vote, Jul 2026, WADA, Half-life, Evidence strength are the same or both unknown.

Field5-Amino-1MQSLU-PP-332
ClassNNMT inhibitor (not a peptide)ERR agonist (not a peptide)
Also called5-amino, 1MQslupp, SLU-PP
Human studies we summarised0 human (0 randomized or controlled) of 4 summarised0 human (0 randomized or controlled) of 7 summarised
Typical study dosesNot reported in study abstractsPubMed search, 11 Oct 2026
Vial sizes sold5 mg, 10 mg5 mg
Related tools

5-Amino-1MQ vs SLU-PP-332

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

Two lab compounds with different targets

5-amino-1MQ is a quinolinium inhibitor of the enzyme NNMT; in obese mice it was paired with a low-fat diet and normalised adiposity.[2]

SLU-PP-332 is an ERR agonist that mimicked exercise-induced benefits on whole-body metabolism in mice.[6]

Together, and in people

A PubMed title and abstract search on 2 Oct 2026 for 5-amino-1MQ with SLU-PP-332 returned 0 records.

Calculated from pubmed query ("5-amino-1MQ"[tiab] OR 5-amino-1-methylquinolinium[tiab]) AND ("SLU-PP-332"[tiab]); search date 2026-10-02; records returned 0; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key 5-amino-1mq__slu-pp-332); no arithmetic applied.

For SLU-PP-332, a systematic review of mouse and cell models states that clinical trials are needed to confirm efficacy and safety in humans.[12]

Status

The Drugs@FDA lookup for SLU-PP-332 returned no match.[13]

The same lookup for 5-amino-1MQ returned no match.[14]

A study of SLU-PP-332 metabolites states that WADA prohibits exercise mimetics, and that identifying metabolites is a step toward detecting misuse.[15]

Common questions

5-amino-1MQ vs SLU-PP-332: what is the difference?

One blocks an enzyme (NNMT), the other activates ERR receptors; both have only mouse or cell data in the sources reviewed.[6]

Can you stack 5-amino-1MQ and SLU-PP-332?

The dataset search found no record of the two being tested together, and a systematic review says clinical trials are needed for SLU-PP-332.[12]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.Scientific reports · 2022PMID 35013352Accessed 2 Oct 2026
  3. 3Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2021PMID 33645410Accessed 2 Oct 2026
  4. 4PubMed search: "5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab] (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: nicotinamide N-methyltransferase[tiab] AND (quinolinium[tiab] OR 5-amino-1MQ[tiab] OR "5-amino-1-methylquinolinium"[tiab] OR 5MQ[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
  7. 7PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: ("5-amino-1MQ"[tiab] OR 5-amino-1-methylquinolinium[tiab]) AND ("SLU-PP-332"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: ("5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (0 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  11. 11PubMed search: ("SLU-PP-332"[tiab] OR "SLU-PP-915"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  12. 12[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].Revista medica de Chile · 2026PMID 42024694Accessed 2 Oct 2026
  13. 13Drugs@FDA (openFDA) search: active ingredient "SLU-PP-332"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  14. 14Drugs@FDA (openFDA) search: active ingredient "5-amino-1MQ"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  15. 15Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.Drug testing and analysis · 2026PMID 41688415Accessed 2 Oct 2026

Found an error? Report a correction.